0000000000386120

AUTHOR

Vanessa Hebditch

showing 2 related works from this author

Advancing the global public health agenda for NAFLD: a consensus statement

2021

Digital

medicine.medical_specialtyCivil societyDelphi methodMEDLINENashMULTIDISCIPLINARY APPROACHDiseaseLATIN-AMERICAN ASSOCIATIONMultidisciplinary approachQUALITY-OF-LIFENon-alcoholic Fatty Liver DiseaseEpidemiologyMedicineHumansHumans; Non-alcoholic Fatty Liver DiseasePOSITION STATEMENTBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.FATTY LIVER-DISEASEBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Hepatologybusiness.industryPublic healthGastroenterologyALCOHOLIC STEATOHEPATITISNONINVASIVE DIAGNOSISmedicine.diseaseObesityCARDIOVASCULAR-DISEASEPRACTICE GUIDELINESFamily medicinePRACTICAL APPROACHHuman medicinebusiness
researchProduct

The Cost of Non-Alcoholic Steatohepatitis (NASH) in Europe and USA: The GAIN Study

2019

Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver disorders. The progressive form of NAFLD, non-alcoholic steatohepatitis (NASH), leads to cirrhosis in a proportion of patients and so is associated with a substantial socio-economic burden which, coupled with a steadily rising prevalence, is becoming a growing public health challenge. The Global Assessment of the Impact of NASH (GAIN) study is a socioeconomic, prevalence-based burden of illness study across Europe (France, Germany, Italy, Spain and the United Kingdom) and the United States to determine the socio-economic burden of NASH in the real-world. Methods: GAIN was a retrospective, cross-sec…

medicine.medical_specialtybusiness.industryPublic healthFatty liverDiseasemedicine.diseaseIndirect costsQuality of lifeInformed consentFamily medicinemedicineSteatohepatitisbusinessSocioeconomic statusSSRN Electronic Journal
researchProduct